Zur Merkliste hinzufügen
Zurück

 

44814-01 - Vorlesung: Target Validation and Identification of Modulators: exemplified by Therapeutics in Immune Pharmacology 1 KP

Semester Herbstsemester 2022
Angebotsmuster Jedes Herbstsemester
Dozierende Christoph Burkhart (christoph.burkhart@unibas.ch)
Thomas Calzascia (thomas.calzascia@unibas.ch)
Tobias Junt (tobias.junt@unibas.ch, BeurteilerIn)
Gisbert Weckbecker (gisbert.weckbecker@unibas.ch)
Lernziele The student will understand
- Concepts of basic immunology and key signaling events in immune cells as prerequisites for the discovery of new targets and immunomodulatory drugs
- The medical need in key immunological disorders such as multiple sclerosis, lupus and transplant rejection
- the discovery und use of standard immunosuppressive drugs such as cyclosporine and rapamycins and their limitations as a motivation for further drug discovery
- The discovery of new immunomodulatory drugs with more specific profiles such as interference with cell migration, co-stimulation and nucleic acid sensing (drugs include natalizumab and fingolimod)
- that PI3 kinase inhibitors offer new opportunities to interfere with the activation and function of various immune cells that are involved in immune disorders or cancer (drugs include idelalisib and duvelisib)
- how activators of immune cells are becoming successful new treatment options for cancer and infections (drugs include anti-CTLA-4 Ab, anti-PD-1 and anti-PD-L1 Abs)
- use of immune cell depletion strategies to fight immune disorders, e.g. MS
Literatur Literature List

Textbooks (in English):
• Kuby Immunology, 8th edition (2018)
• Janeway's Immunobiology, 10th edition (2022)
• Immunology. A Short Course. 8th Edition (2021), R. Coico G. Sunshine
• Cellular and Molecular Immunology, 10th Edition (2021), A. Abbas, A. Lichtman, S. Pillai

Check out “Global Immunotalks” on Youtube for related topics


Reviews and Papers:
Lectures 1 and 2 (Junt)

Edner NM, Carlesso G, Rush JS, Walker LSK., Targeting co-stimulatory molecules in autoimmune disease. Nat Rev Drug Discov. 2020 Dec;19(12):860-883
Junt T, Barchet W (2015), Translating nucleic acid-sensing pathways into therapies. Nat Rev Immunol 15, 529
Ley K et al (2016), Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov 15 (3), 173.
Chun J, Brinkmann VA (2011), Mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 12(64), 213.


Lectures 3 and 4 (Weckbecker)

Waring M et al (2015) An analysis of the attrition of drug candidates from four major pharmaceutical companies Nat Rev Drug Discov, online, 1.
Haijuan Y et al (2013) mTOR kinase structure, mechanism and regulation Nature 497, 217.
Gurk-Turner,C et al (2012) A Comprehensive Review of Everolimus Clinical Reports: A New Mammalian Target of Rapamycin Inhibitor Transplantation 94, 659.
Amber N. Carrier et al (2022) Xenotransplantation: A New Era (Review) Frontiers in Immunology 13, 1-11
B Sharrack, J Petrie, A Coles, JA Snowden (2022) Is stem cell transplantation safe and effective in multiple sclerosis? BMJ, 377.
Willison, A.G., Ruck, T., Lenz, G. et al. (2022) The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. J Neurol 269, 3937–3958.


Lecture 5 (Calzascia)

Ribas A and Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade, Science 359(6382), 1350
Chen DS and Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle, Immunity 39(1): 1.
Khalil DN et al (2016) The future of cancer treatment: immunomodulation, CARs and combination therapy, Nat Rev Clin Onc 13, 273.
Met Ö et al (2019) Principles of adoptive T cell therapy in cancer, Semin Immunopathol 41(1), 49


Lecture 6 (Burkhart)

Vanhaesebroeck B et al (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11(5), 329.
Lucas C et al (2014) Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol 15, 88.
Rao VK et al (2017) Effective “activated PI3Kdelta syndrome”-targeted therapy with the PI3Kdelta inhibitor leniolisib. Blood 130, 2307
Vanhaesebroeck B et al (2021) PI3K inhibitors are finally coming of age. Nature Rev Drug Discov 20 (10), 471
Bemerkungen Researchers in Basel have contributed significantly to the fields of immuno-pharmacology and inflammation (e.g. cyclosporine, everolimus, ofatumumab, ocrelizumab, fingolimod, PI3 kinase inhibitors, diclofenac).

Film and sound recordings during the course are strictly forbidden (recorders may be confiscated)
Weblink Department of Pharmaceutical Sciences

 

Teilnahmebedingungen Completed Bachelor degree
Unterrichtssprache Englisch
Einsatz digitaler Medien kein spezifischer Einsatz

 

Intervall wöchentlich
Datum 21.09.2022 – 26.10.2022
Zeit Mittwoch, 10.15-12.00 Biozentrum, Seminarraum U1.191
Datum Zeit Raum
Mittwoch 21.09.2022 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 28.09.2022 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 05.10.2022 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 12.10.2022 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 19.10.2022 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Mittwoch 26.10.2022 10.15-12.00 Uhr Biozentrum, Seminarraum U1.191
Module Modul: Target Identification/Validation to Discovery of Modulators (Masterstudium: Drug Sciences)
Modul: Vertiefung Medizinische Nanowissenschaften (Masterstudium: Nanowissenschaften)
Wahlbereich Master Pharmazie: Empfehlungen (Masterstudium: Pharmazie)
Leistungsüberprüfung Lehrveranst.-begleitend
Hinweise zur Leistungsüberprüfung refer to this link: https://pharma.unibas.ch/en/education/assessments-and-credit-points/continuous-assessments/
An-/Abmeldung zur Leistungsüberprüfung An-/Abmelden: Belegen resp. Stornieren der Belegung via MOnA
Wiederholungsprüfung keine Wiederholungsprüfung
Skala 1-6 0,5
Wiederholtes Belegen beliebig wiederholbar
Zuständige Fakultät Philosophisch-Naturwissenschaftliche Fakultät, studiendekanat-philnat@unibas.ch
Anbietende Organisationseinheit Departement Pharmazeutische Wissenschaften

Zurück